Literature DB >> 7544117

Development of a cleavage-site-specific monoclonal antibody for detecting metalloproteinase-derived aggrecan fragments: detection of fragments in human synovial fluids.

A J Fosang1, K Last, P Gardiner, D C Jackson, L Brown.   

Abstract

We have developed a monoclonal antibody AF-28 that specifically recognizes a neo-epitope on polypeptides with N-terminal FFGVG ... sequences. This sequence is found at the N-terminus of aggrecan fragments that have been digested with matrix metalloproteinases (MMPs). By immunoblotting, monoclonal antibody AF-28 specifically detected G2 fragments derived from an aggrecan G1-G2 substrate digested with stromelysin, collagenase, gelatinase and matrilysin, but failed to detect G2 fragments obtained from elastase, trypsin or cathepsin B digests. Undigested G1-G2 was not detected. In addition, AF-28 antibody detected fragments derived from whole aggrecan and this detection did not require prior treatment with chondroitinase or keratanase. Competition experiments confirmed that peptides containing internal ... FFGVG ... sequences were not detected by the antibody, while native MMP-digested aggrecan fragments and a synthetic 32-mer peptide with FFGVG ... N-termini were equally competitive on a molar basis. An FFGVG 5-mer, and an FGVGGEEDI9-mer which lacked the N-terminal phenylalanine residue, were 50 times and 230 times respectively less competitive than the FFGVG ... 32-mer. Two fragments from the interglobular domain, F342-F373 and F342-D441, that are predicted products of G1-G2 digestion by neutrophil collagenase but have not previously been detected, could be detected with AF-28. The epitope recognized by AF-28 was also detected in human synovial fluids by Western blot analysis. A broad band of 100-200 kDa was detected in some patients and a dominant band of 40-60 kDa was found in two patients. The size of this small fragment corresponds with that seen for the porcine F342-E373 product and may represent the natural physiological product of aggrecan cleaved in vivo at both the MMP site (... DIPEN341 decreases F342FGVG ...) and the aggrecanase site (... ITEGE373 decreases A374RGSVI ...).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7544117      PMCID: PMC1135893          DOI: 10.1042/bj3100337

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  35 in total

1.  Crystallization of recombinant rat cathepsin B.

Authors:  X Lee; F R Ahmed; T Hirama; C P Huber; D R Rose; R To; S Hasnain; A Tam; J S Mort
Journal:  J Biol Chem       Date:  1990-04-15       Impact factor: 5.157

2.  The antigenic determinants recognized by three monoclonal antibodies to keratan sulphate involve sulphated hepta- or larger oligosaccharides of the poly(N-acetyllactosamine) series.

Authors:  H Mehmet; P Scudder; P W Tang; E F Hounsell; B Caterson; T Feizi
Journal:  Eur J Biochem       Date:  1986-06-02

3.  Electrophoresis of 35S-labeled proteoglycans on polyacrylamide-agarose composite gels and their visualization by fluorography.

Authors:  S L Carney; M T Bayliss; J M Collier; H Muir
Journal:  Anal Biochem       Date:  1986-07       Impact factor: 3.365

4.  Electrophoretic analysis of the major polypeptides of the human erythrocyte membrane.

Authors:  G Fairbanks; T L Steck; D F Wallach
Journal:  Biochemistry       Date:  1971-06-22       Impact factor: 3.162

5.  A method for preparing beta-hCG COOH peptide-carrier conjugates of predictable composition.

Authors:  A C Lee; J E Powell; G W Tregear; H D Niall; V C Stevens
Journal:  Mol Immunol       Date:  1980-06       Impact factor: 4.407

6.  Isolation of the N-terminal globular protein domains from cartilage proteoglycans. Identification of G2 domain and its lack of interaction with hyaluronate and link protein.

Authors:  A J Fosang; T E Hardingham
Journal:  Biochem J       Date:  1989-08-01       Impact factor: 3.857

7.  Immunodetection and characterization of the degradation of cartilage proteoglycans in vitro and in vivo.

Authors:  A R Poole; J Witter; N Roberts; P J Roughley; C Webber; I Campbell
Journal:  J Rheumatol       Date:  1987-05       Impact factor: 4.666

8.  The action of human articular-cartilage metalloproteinase on proteoglycan and link protein. Similarities between products of degradation in situ and in vitro.

Authors:  I K Campbell; P J Roughley; J S Mort
Journal:  Biochem J       Date:  1986-07-01       Impact factor: 3.857

9.  Monoclonal antibodies that specifically recognize neoepitope sequences generated by 'aggrecanase' and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro.

Authors:  C E Hughes; B Caterson; A J Fosang; P J Roughley; J S Mort
Journal:  Biochem J       Date:  1995-02-01       Impact factor: 3.857

10.  The immunologic detection and characterization of cartilage proteoglycan degradation products in synovial fluids of patients with arthritis.

Authors:  J Witter; P J Roughley; C Webber; N Roberts; E Keystone; A R Poole
Journal:  Arthritis Rheum       Date:  1987-05
View more
  23 in total

Review 1.  The use of cleavage site specific antibodies to delineate protein processing and breakdown pathways.

Authors:  J S Mort; D J Buttle
Journal:  Mol Pathol       Date:  1999-02

2.  Catabolism of aggrecan, decorin and biglycan in tendon.

Authors:  S G Rees; C R Flannery; C B Little; C E Hughes; B Caterson; C M Dent
Journal:  Biochem J       Date:  2000-08-15       Impact factor: 3.857

Review 3.  Proteoglycomics: recent progress and future challenges.

Authors:  Mellisa Ly; Tatiana N Laremore; Robert J Linhardt
Journal:  OMICS       Date:  2010-08

4.  Adamts5-/- Mice Exhibit Altered Aggrecan Proteolytic Profiles That Correlate With Ascending Aortic Anomalies.

Authors:  Loren E Dupuis; E Lockett Nelson; Brittany Hozik; Sarah C Porto; Alexandra Rogers-DeCotes; Amanda Fosang; Christine B Kern
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-08-01       Impact factor: 8.311

5.  Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro.

Authors:  C B Little; C R Flannery; C E Hughes; J S Mort; P J Roughley; C Dent; B Caterson
Journal:  Biochem J       Date:  1999-11-15       Impact factor: 3.857

6.  Characterization of helical cleavages in type II collagen generated by matrixins.

Authors:  M Vankemmelbeke; P M Dekeyser; A P Hollander; D J Buttle; J Demeester
Journal:  Biochem J       Date:  1998-03-01       Impact factor: 3.857

7.  Matrix metalloproteinases are not essential for aggrecan turnover during normal skeletal growth and development.

Authors:  Christopher B Little; Clare T Meeker; Rosalind M Hembry; Natalie A Sims; Kate E Lawlor; Sue B Golub; Karena Last; Amanda J Fosang
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

8.  The 45 kDa collagen-binding fragment of fibronectin induces matrix metalloproteinase-13 synthesis by chondrocytes and aggrecan degradation by aggrecanases.

Authors:  Heather Stanton; Linh Ung; Amanda J Fosang
Journal:  Biochem J       Date:  2002-05-15       Impact factor: 3.857

9.  Investigating ADAMTS-mediated aggrecanolysis in mouse cartilage.

Authors:  Heather Stanton; Suzanne B Golub; Fraser M Rogerson; Karena Last; Christopher B Little; Amanda J Fosang
Journal:  Nat Protoc       Date:  2011-03-03       Impact factor: 13.491

10.  An aggrecan fragment drives osteoarthritis pain through Toll-like receptor 2.

Authors:  Rachel E Miller; Shingo Ishihara; Phuong B Tran; Suzanne B Golub; Karena Last; Richard J Miller; Amanda J Fosang; Anne-Marie Malfait
Journal:  JCI Insight       Date:  2018-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.